Evaluating endocrine disrupting chemicals: A perspective on the novel assessments in CLARITY‐BPA
Kembra L. Howdeshell, Brandiese E. J. Beverly, Robyn B. Blain, Alexandra E. Goldstone, Pamela A. Hartman, Courtney R. Lemeris, Retha R. Newbold, Andrew A. Rooney, John R. Bucher - Health, Toxicology and Mutagenesis
- Developmental Biology
- Toxicology
- Embryology
- Pediatrics, Perinatology and Child Health
Abstract
Background
The Consortium Linking Academic and Regulatory Insights on Bisphenol A Toxicity (CLARITY‐BPA) was a collaborative research effort to better link academic research with governmental guideline studies. This review explores the secondary goal of CLARITY‐BPA: to identify endpoints or technologies from CLARITY‐BPA and prior/concurrent literature from these laboratories that may enhance the capacity of rodent toxicity studies to detect endocrine disrupting chemicals (EDCs).
Methods
A systematic literature search was conducted with search terms for BPA and the CLARITY‐BPA participants. Relevant studies employed a laboratory rodent model and reported results on 1 of the 10 organs/organ systems evaluated in CLARITY‐BPA (brain and behavior, cardiac, immune, mammary gland, ovary, penile function, prostate gland and urethra, testis and epididymis, thyroid hormone and metabolism, and uterus). Study design and findings were summarized, and a risk‐of‐bias assessment was conducted.
Results
Several endpoints and methods were identified as potentially helpful to detect effects of EDCs. For example, molecular and quantitative morphological approaches were sensitive in detecting alterations in early postnatal development of the brain, ovary, and mammary glands. Hormone challenge studies mimicking human aging reported increased susceptibility of the prostate to disease following developmental BPA exposure. Statistical analyses for nonmonotonic dose responses, and computational approaches assessing multiple treatment‐related outcomes concurrently in linked hormone‐sensitive organ systems, reported effects at low BPA doses.
Conclusions
This review provided an opportunity to evaluate the unique insights provided by nontraditional assessments in CLARITY‐BPA to identify technologies and endpoints to enhance detection of EDCs in future studies.